Faron Pharmaceuticals Ltd: Director Dealing

Faron Pharmaceuticals Ltd | Company announcement | March 25, 2026 at 10:00:00 EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Sirpa Jalkanen, Scientific founder of the Company and spouse of Board member Markku Jalkanen, subscribed 100,008 ordinary shares in Faron at price of €0.5 per share on 24 March 2026, pursuant to the Rights Issue announced by the Company on 10 March 2026.

Further details are set out in the Notification of Dealing Form below.

For more information, please contact:

IR Partners, Finland (Media) Kare Laukkanen	[phone] / [phone] [e-mail]
FINN Partners, US (Media)  Alyssa Paldo	[phone]  [e-mail]
Cairn Financial Advisers LLP (Nominated Adviser and Broker) Sandy Jamieson, Jo Turner	[phone]
Sisu Partners Oy (Certified Adviser on Nasdaq First North) Juha Karttunen Jukka Järvelä	[phone] [phone]

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Sirpa Jalkanen
2	Reason for notification
a.	Position/Status	PCA
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Faron Pharmaceuticals Ltd.
b.	LEI	7437009H31TO1DC0EB42
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Subscription for new ordinary shares, pursuant to a rights issue ISIN: FI4000153309
b.	Nature of the transaction	Subscription
			Price(s) per share (p)	Volume(s)
			EUR 0.5	100,008
d.	Aggregated information Volume Price	Transaction details (a) (1): Volume 100,008 Unit price: 0.5 EUR
e.	Date of the transaction	24.3.2026
f.	Place of the transaction	Nasdaq First North Growth Market